Index reshuffle puts BrightSpring Health Services in focus
BrightSpring Health Services (BTSG) moved from the S&P 600 to the S&P 400 Health Care index, a reshuffle that can change how index funds and institutional investors trade the stock.
See our latest analysis for BrightSpring Health Services.
BrightSpring Health Services has seen strong momentum build, with an 84.09% year to date share price return and a very large 254.42% 1 year total shareholder return. The latest index shift and recent 1 day gain of 3.71% suggest investors are reassessing its risk and growth outlook.
If the index reshuffle has you thinking about where else capital might rotate, this is a good moment to look across other healthcare opportunities using the 39 healthcare AI stocks
BrightSpring Health Services now sits in a bigger index and carries strong recent returns, but that mix of scale and momentum only matters if the stock price still reflects the underlying business, or already assumes too much.
Most Popular Narrative: 10% Overvalued
According to the latest narrative, BrightSpring Health Services has a fair value of $70.59, slightly below the last close at $70.69, which frames the current enthusiasm as only modestly stretched rather than extreme.
The real business is not home health. It is pharmacy. Roughly 80% of revenue comes from specialty and institutional pharmacy services:
Want to know what sits behind that infrastructure style view of BrightSpring Health Services? The narrative leans on a shift from restructuring drag to scale driven earnings, with profit margins and cash generation playing a central role in how that fair value is built.
Result: Fair Value of $70.59 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BrightSpring Health Services still faces potential setbacks if pharmacy reimbursement changes or if integration efforts fail to deliver the margins assumed in this narrative.
Find out about the key risks to this BrightSpring Health Services narrative.
Another View: BrightSpring Health Services and the cash flow gap
While the popular narrative pegs BrightSpring Health Services around fair value at $70.59, the SWS DCF model paints a very different picture, with a future cash flow value of $175.21 that frames the current $70.69 share price as trading at a large discount.
DCF models are sensitive to long term assumptions, so investors weighing this gap may want to ask whether the market is too cautious on BrightSpring Health Services or whether the cash flow outlook is simply too optimistic.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BrightSpring Health Services for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals on BrightSpring Health Services in mind, take a moment to weigh both the concerns and the upside so you can form a clear view with the 3 key rewards and 1 important warning sign
Looking for more BrightSpring Health Services investment ideas?
If BrightSpring Health Services has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.
- Target stronger fundamentals by checking companies that score well on balance sheet strength and cash flow quality using the solid balance sheet and fundamentals stocks screener (47 results).
- Hunt for pricing gaps where quality and value meet through the 47 high quality undervalued stocks.
- Prioritize resilience by focusing on companies with steadier risk profiles via the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com